Dermatological Drugs, Topical Agents, and Cosmetics

Black, Adrienne T.

doi:10.1016/bs.seda.2016.08.002

Cited by 1 publication

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ingenol mebutate is available in 0.015% and 0.05% gels and it is administered for 2 to 7 consecutive days, with clearance occurring in approximately 63% of patients [ 31 , 46 , 47 ]. While its application is advantageous due to self-administration and short application periods, it is usually associated with adverse events, including erythema, edema, pruritus, and pain [ 31 , 47 , 48 ].…”

Section: Topical Field Treatmentsmentioning

confidence: 99%

Regenerative Wound Dressings for Skin Cancer

Pavel

Chircov

Rădulescu

et al. 2020

Cancers

View full text Add to dashboard Cite

Skin cancer is considered the most prevalent cancer type globally, with a continuously increasing prevalence and mortality growth rate. Additionally, the high risk of recurrence makes skin cancer treatment among the most expensive of all cancers, with average costs estimated to double within 5 years. Although tumor excision is the most effective approach among the available strategies, surgical interventions could be disfiguring, requiring additional skin grafts for covering the defects. In this context, post-surgery management should involve the application of wound dressings for promoting skin regeneration and preventing tumor recurrence and microbial infections, which still represents a considerable clinical challenge. Therefore, this paper aims to provide an up-to-date overview regarding the current status of regenerative wound dressings for skin cancer therapy. Specifically, the recent discoveries in natural biocompounds as anti-cancer agents for skin cancer treatment and the most intensively studied biomaterials for bioactive wound dressing development will be described.

show abstract